GoodRx (GDRX) Stock Price, News & Analysis

Company Overview

GoodRx Holdings, Inc. (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs. Users can connect with licensed healthcare professionals online for diagnostics and treatment, with the option to have prescriptions delivered to their home or sent to a local pharmacy. GoodRx also markets GoodRx Gold, a membership program that further reduces out-of­-pocket costs for prescription drugs, as well as GoodRx Shop, an e-commerce marketplace for health and wellness products.

Founded in 2011, GoodRx is headquartered in Santa Monica, California, and focuses its operations on the U.S. market. The company went public in 2020, listing its shares on the Nasdaq exchange. Over the years, GoodRx has expanded its partnerships with pharmacy benefit managers, major retail pharmacy chains, and pharmaceutical manufacturers to broaden its discount offerings and enhance access to affordable medications for millions of Americans.

GoodRx’s leadership team includes co-founder Doug Hirsch, who serves as Executive Chairman, and Trevor Bezdek, who holds the role of Chief Executive Officer. Under their guidance, the company has pursued strategic acquisitions and product innovations aimed at simplifying healthcare navigation, improving price transparency and expanding virtual care services. GoodRx continues to evolve its platform to address the changing needs of consumers, healthcare providers and pharmacy partners nationwide.

Key Stats

• Today's Range: $2.93 to $3.03
• 50-Day Range: $2.36 to $3.08
• 52-Week Range: $1.77 to $5.81
• Volume: 717,737 shs
• Average Volume: 1.04 million shs
• Market Capitalization: $1.01 billion
• P/E Ratio: 49.17
• Dividend Yield: N/A
• Price Target: $3.81
• Consensus Rating: Hold

GoodRx Stock Analysis - MarketRank™

GoodRx scored higher than 77% of companies evaluated by MarketBeat, and ranked 174th out of 849 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Hold

Consensus Rating

GoodRx has received a consensus rating of Hold. The company's average rating score is 2.13, and is based on no strong buy ratings, 5 buy ratings, 7 hold ratings, and 3 sell ratings.

Upside Potential

GoodRx has a consensus price target of $3.81, representing about 29.2% upside from its current price of $2.95.

Amount of Analyst Coverage

GoodRx has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 17.65%

Earnings Growth

Earnings for GoodRx are expected to grow by 17.65% in the coming year, from $0.17 to $0.20 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of GoodRx is 49.17, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 45.99.

Price to Earnings Ratio vs. Sector

The P/E ratio of GoodRx is 49.17, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.22.

Price to Earnings Growth Ratio

GoodRx has a PEG Ratio of 1.36. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

GoodRx has a P/B Ratio of 1.63. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.08% of the float of GoodRx has been sold short.

Short Interest Ratio / Days to Cover

GoodRx has a short interest ratio ("days to cover") of 5.57.

Change versus previous month

Short interest in GoodRx has recently decreased by 10.55%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

GoodRx does not currently pay a dividend.

Dividend Growth

GoodRx does not have a long track record of dividend growth.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: 0.50

News Sentiment

GoodRx has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for GoodRx this week, compared to 4 articles on an average week.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, GoodRx insiders have not sold or bought any company stock.

Percentage Held by Insiders

5.87% of the stock of GoodRx is held by insiders.

Percentage Held by Institutions

63.77% of the stock of GoodRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/06/2026
• Today: 7/10/2026
• Next Earnings (Estimated): 8/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Business Services
• Current Symbol: NASDAQ:GDRX
• CIK: 1809519
• Web: www.goodrx.com
• Phone: 855-268-2822
• Fax: N/A
• Employees: 950
• Year Founded: 2011

Price Target and Rating

• Average Price Target for GoodRx: $3.81
• High Price Target: $6.00
• Low Price Target: $2.75
• Potential Upside/Downside: +29.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.13
• Research Coverage: 15 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.06
• Trailing P/E Ratio: 49.17
• Forward P/E Ratio: 17.35
• P/E Growth: 1.36
• Net Income: $30.44 million
• Net Margins: 2.61%
• Pretax Margin: 5.78%
• Return on Equity: 7.90%
• Return on Assets: 3.23%

Debt

• Debt-to-Equity Ratio: 0.78
• Current Ratio: 1.47
• Quick Ratio: 1.47

Sales & Book Value

• Annual Sales: $796.85 million
• Price / Sales: 1.27
• Cash Flow: $0.40 per share
• Price / Cash Flow: 7.35
• Book Value: $1.81 per share
• Price / Book: 1.63

Miscellaneous

• Outstanding Shares: 342,570,000
• Free Float: 322,465,000
• Market Cap: $1.01 billion
• Optionable: Optionable
• Beta: 1.60